From April 1, 2022 to June 30, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 134,591,821 shares, representing 8.54% for $13,605.46 million under the buyback announced on February 15, 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167.3 USD | -0.30% | +1.60% | +7.95% |
Apr. 25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
Apr. 25 | AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.95% | 297B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B | |
+2.07% | 117B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Tranche Update on AbbVie Inc.'s Equity Buyback Plan announced on February 15, 2018.